Continuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1...
diaTribe Convenes International Consensus to Guide Diabetes Technology Use During Pregnancy
Expert recommendations provide crucial guidance to leverage CGM and AID during pregnancy. SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ -- The diaTribe Foundation announces the publication of the first international consensus statement on the use of...